Amgen says Lumakras cuts risk of lung cancer progression by 34 per cent Reuters Sep 12, 2022 The medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13 per cent of non-small cell…
Amgen says Lumakras plus immunotherapy for lung cancer needs further study Reuters Aug 8, 2022 The findings are the first indication of how well Lumakras works in combination with drugs that help the immune system attack…
FDA approves first targetted therapy to treat aggressive form of lung cancer EP News Bureau May 7, 2020 The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta The US Food and Drug…
